GEMINI THERAPEUTICS INC (GMTX) Stock Price, Quote, News and Overview
NASDAQ:GMTX - Nasdaq - US36870G1058 - Common Stock - Currency: USD
GMTX Quote, Performance and Key Statistics
1.35
0 (0%)
The current stock price of GMTX is 1.35 USD. In the past month the price decreased by -21.51%. In the past year, price decreased by -53.61%.
GMTX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About GMTX
Company Profile
Gemini Therapeutics, Inc. is a clinical-stage precision medicine company. The company is headquartered in Cambridge, Massachusetts and currently employs 31 full-time employees. The company went IPO on 2020-08-12. The firm is principally focused on developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration (AMD). The firm's lead product candidate, GEM103, is a recombinant form of the human complement factor H protein (CFH) and is designed to address both complement hyperactivity and restore retinal health in patients with AMD. Its Pipeline of product candidate includes (adeno-associated virus) AAV-CFH, AAV-CFI, AAV-Ab, GEM104 and GEM307. Its AAV-CFH program is complementary to GEM103 program, as AAV-CFH to construct that express GEM103 continuously at a therapeutic level. Its pipeline is designed to develop treatments for genetically subpopulations of patients suffering from dry AMD and linked diseases. The firm do not own or operate manufacturing facilities for the production of clinical or commercial quantities of its product candidates.
Company Info
GEMINI THERAPEUTICS INC
300 One Kendall Square, 3Rd Floor, Suite 4500
Cambridge MASSACHUSETTS 94111 US
CEO: Jason Meyenburg
Employees: 31
Company Website: https://geminitherapeutics.com/
Phone: 16174014400.0
GEMINI THERAPEUTICS INC / GMTX FAQ
What is the stock price of GEMINI THERAPEUTICS INC today?
The current stock price of GMTX is 1.35 USD.
What is the ticker symbol for GEMINI THERAPEUTICS INC stock?
The exchange symbol of GEMINI THERAPEUTICS INC is GMTX and it is listed on the Nasdaq exchange.
On which exchange is GMTX stock listed?
GMTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for GEMINI THERAPEUTICS INC stock?
6 analysts have analysed GMTX and the average price target is 1.53 USD. This implies a price increase of 13.33% is expected in the next year compared to the current price of 1.35. Check the GEMINI THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is GEMINI THERAPEUTICS INC worth?
GEMINI THERAPEUTICS INC (GMTX) has a market capitalization of 58.45M USD. This makes GMTX a Micro Cap stock.
How many employees does GEMINI THERAPEUTICS INC have?
GEMINI THERAPEUTICS INC (GMTX) currently has 31 employees.
What are the support and resistance levels for GEMINI THERAPEUTICS INC (GMTX) stock?
GEMINI THERAPEUTICS INC (GMTX) has a resistance level at 1.35. Check the full technical report for a detailed analysis of GMTX support and resistance levels.
Should I buy GEMINI THERAPEUTICS INC (GMTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GMTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GMTX, evaluating the profitability, health, valuation and growth aspects
- GEMINI THERAPEUTICS INC (GMTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- GEMINI THERAPEUTICS INC (GMTX) Sales and EPS estimates to see what analysts future expectations are.
- GEMINI THERAPEUTICS INC (GMTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- GEMINI THERAPEUTICS INC (GMTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- GEMINI THERAPEUTICS INC (GMTX) Stock Chart to make your own analysis
- GEMINI THERAPEUTICS INC (GMTX) Latest news and press-releases to stay up to date.
Does GEMINI THERAPEUTICS INC (GMTX) stock pay dividends?
GMTX does not pay a dividend.
When does GEMINI THERAPEUTICS INC (GMTX) report earnings?
GEMINI THERAPEUTICS INC (GMTX) will report earnings on 2023-03-08.
What is the Price/Earnings (PE) ratio of GEMINI THERAPEUTICS INC (GMTX)?
GEMINI THERAPEUTICS INC (GMTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.81).
GMTX Technical Analysis
GMTX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to GMTX. No worries on liquidiy or solvency for GMTX as it has an excellent financial health rating, but there are worries on the profitability.
GMTX Financial Highlights
Over the last trailing twelve months GMTX reported a non-GAAP Earnings per Share(EPS) of -1.81. The EPS increased by 29.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
GMTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to GMTX. The Buy consensus is the average rating of analysts ratings from 6 analysts.